Redcare Pharmacy Accelerates Growth Momentum, Expands Profitability and Raises Full-Year 2026 Guidance
Redcare Pharmacy has reported stronger-than-anticipated trading performance during the first two months of the second quarter of 2026, prompting the company to upgrade its financial outlook for the full year. The online pharmacy group said revenue growth accelerated compared with the first quarter, supported by robust demand across both prescription (Rx) and non-prescription (non-Rx) businesses. Improved operational execution, stronger customer engagement, and continued market share gains have also contributed to rising profitability.
The company’s preliminary figures for April and May demonstrate sustained momentum across its key markets, particularly in the DACH region—Germany, Austria, and Switzerland—where prescription and over-the-counter products delivered solid gains. On the basis of this encouraging performance, Redcare Pharmacy has revised its revenue and earnings expectations upward for 2026.
Strong Quarter-to-Date Performance Exceeds Expectations
According to the company, trading during the opening two months of the second quarter has outpaced internal forecasts, with growth accelerating from levels recorded during the first quarter of the year. Revenue trends remained consistent throughout April and May, highlighting the strength and resilience of Redcare Pharmacy’s business model.
The company noted that both prescription medicines and non-prescription healthcare products contributed to the stronger results. In Germany, non-Rx sales growth improved considerably, rising from 9% in the first quarter to 12% in April before accelerating further to 16% in May. This steady increase reflects growing consumer demand and the effectiveness of the company’s customer experience initiatives.
The encouraging quarter-to-date figures reinforce Redcare Pharmacy’s position as one of Europe’s leading digital healthcare and pharmacy platforms, with increasing consumer adoption of online pharmaceutical services continuing to support expansion.
CEO Highlights Market Share Gains and Operational Improvements
Commenting on the company’s performance, Chief Executive Officer Olaf Heinrich emphasized the resilience of Redcare Pharmacy’s operations and its ability to generate growth across multiple business segments.
“Our trading shows the robustness and momentum of our business, with growth across Rx and non-Rx,” Heinrich said. “We continue to gain market share and improve our profitability as we improve customer experience and execution in general.”
Management believes that enhanced service quality, efficient marketing investments, and a broader customer base are helping the company strengthen its competitive position while maintaining profitable growth.
DACH Region Drives Accelerated Growth
The DACH segment remained the primary engine of growth during the first two months of the second quarter. Revenue in the region increased by 21% year over year, supported by continued strength in prescription medicine sales and an acceleration in demand for non-prescription products.
Germany, the company’s largest market, played a particularly significant role in driving growth. Non-prescription sales in the country accelerated to 14% year-over-year growth during April and May, representing a substantial improvement compared with the first quarter.
Meanwhile, prescription medicine sales maintained strong momentum. Across the DACH region, total Rx revenue rose 33% year over year. Germany delivered especially impressive results, with prescription sales increasing by 57%, surpassing the already robust 55% growth achieved during the first quarter.
The expansion of Germany’s e-prescription ecosystem has continued to create favorable conditions for online pharmacy providers. Redcare Pharmacy has successfully capitalized on these opportunities, enabling it to capture a growing share of the market while strengthening customer loyalty.
Prescription Business Continues to Expand
Prescription medicines have become an increasingly important contributor to Redcare Pharmacy’s growth strategy. The rapid adoption of electronic prescriptions in Germany has accelerated the transition toward digital healthcare services, benefiting online pharmacy operators with strong technological capabilities and nationwide delivery networks.
The company’s Rx segment has consistently delivered high growth rates throughout 2026. Germany remains the most dynamic market, with prescription revenues increasing at a pace that exceeds earlier expectations.
Management believes that the digitalization of healthcare and the broader adoption of e-prescriptions will continue to provide long-term growth opportunities. As patients become more accustomed to digital healthcare solutions, demand for online pharmaceutical services is expected to increase further.
International Segment Maintains Consistent Momentum
Outside the DACH region, Redcare Pharmacy’s International segment continued to post solid results. Revenue growth during April and May reached 16%, matching the growth rate recorded during the first quarter.
The company noted that nearly all international markets contributed positively to this performance, demonstrating the broad-based nature of its expansion strategy. Stable growth across multiple countries highlights Redcare Pharmacy’s ability to scale its business model beyond its core German market.
The International segment remains an important pillar of the company’s long-term strategy, offering diversification and additional opportunities for growth. By leveraging digital platforms and improving customer engagement across Europe, Redcare Pharmacy aims to strengthen its presence in key markets while maintaining operational efficiency.
Profitability Continues to Improve
In addition to stronger revenue growth, Redcare Pharmacy reported continued improvement in its adjusted EBITDA margin compared with the previous year.
Management attributed the increase in profitability primarily to two factors:
- Strong growth in the higher-margin non-prescription business within the DACH region.
- More efficient and targeted marketing expenditures.
The company has focused on optimizing customer acquisition costs while increasing retention rates, allowing it to enhance profitability without sacrificing growth.
As scale increases, Redcare Pharmacy expects operating leverage to improve further, creating additional opportunities to expand margins over time. The combination of strong revenue growth and disciplined cost management is helping the company deliver sustainable earnings improvements.
Full-Year 2026 Guidance Raised
Buoyed by the stronger-than-expected trading performance during the second quarter, Redcare Pharmacy has increased its financial guidance for 2026.
Total Revenue Growth
The company now expects overall revenue growth between 15% and 17% for the year, up from its previous forecast of 13% to 15%.
This upgraded outlook reflects continued momentum across both prescription and non-prescription businesses and confidence in the sustainability of current growth trends.
Non-Prescription Business
Growth in the non-Rx segment is now projected to range between 10% and 12%, compared with the earlier guidance of 8% to 10%.
The acceleration in Germany’s over-the-counter business, particularly during April and May, has provided management with greater confidence regarding future demand patterns.
Prescription Revenue in Germany
Redcare Pharmacy also increased its expectations for prescription medicine sales in Germany.
The company now forecasts Rx revenue between €680 million and €720 million in 2026, representing annual growth of approximately 35% to 43%.
Previously, management had guided for prescription sales exceeding €670 million. The revised outlook reflects stronger-than-expected adoption of electronic prescriptions and continued market share gains.
Adjusted EBITDA Margin
The adjusted EBITDA margin outlook has also been upgraded.
Redcare Pharmacy now expects an adjusted EBITDA margin between 2.5% and 3.0%, compared with previous guidance of more than 2.5%.
The improved profitability outlook demonstrates management’s confidence in its ability to balance growth with operational efficiency.
Customer Experience and Execution Remain Strategic Priorities
A key factor behind Redcare Pharmacy’s success has been its ongoing focus on enhancing customer experience. Investments in digital infrastructure, logistics capabilities, and service quality have enabled the company to deliver faster and more reliable pharmaceutical services to consumers.
Management believes that customer satisfaction and operational excellence are critical components of long-term success in the highly competitive online pharmacy market.
Efficient marketing strategies have also contributed to improved financial performance. By focusing on customer retention and targeted campaigns, the company has been able to optimize spending while supporting sustainable growth.
Favorable Industry Trends Support Long-Term Expansion
The European digital healthcare market continues to benefit from several structural growth drivers, including:
- Increasing consumer preference for online healthcare services.
- Growing adoption of electronic prescriptions.
- Aging populations and rising healthcare demand.
- Expansion of digital health ecosystems.
- Improved logistics and technological capabilities.
These trends are creating favorable conditions for companies such as Redcare Pharmacy, which combines technology-driven operations with a broad product portfolio.
As healthcare systems across Europe continue their digital transformation, online pharmacies are expected to play an increasingly important role in medication delivery and patient care.
Redcare Pharmacy is scheduled to release its full second-quarter 2026 financial results on July 29, 2026. The company will also host its quarterly conference call on the same day to discuss performance and provide further insights into its outlook.
Management indicated that no additional trading updates will be issued before the publication of second-quarter results.
With revenue growth accelerating, profitability improving, and market share expanding, Redcare Pharmacy enters the second half of 2026 with strong momentum. The upgraded guidance reflects management’s confidence in the company’s strategy and underscores its position as one of Europe’s fastest-growing digital pharmacy businesses. As demand for online healthcare services continues to rise, Redcare Pharmacy appears well positioned to capitalize on long-term industry trends while delivering sustainable growth and enhanced shareholder value.
Source link: https://www.redcare-pharmacy.com/
